- 1、原创力文档(book118)网站文档一经付费(服务费),不意味着购买了该文档的版权,仅供个人/单位学习、研究之用,不得用于商业用途,未经授权,严禁复制、发行、汇编、翻译或者网络传播等,侵权必究。。
- 2、本站所有内容均由合作方或网友上传,本站不对文档的完整性、权威性及其观点立场正确性做任何保证或承诺!文档内容仅供研究参考,付费前请自行鉴别。如您付费,意味着您自己接受本站规则且自行承担风险,本站不退款、不进行额外附加服务;查看《如何避免下载的几个坑》。如果您已付费下载过本站文档,您可以点击 这里二次下载。
- 3、如文档侵犯商业秘密、侵犯著作权、侵犯人身权等,请点击“版权申诉”(推荐),也可以打举报电话:400-050-0827(电话支持时间:9:00-18:30)。
- 4、该文档为VIP文档,如果想要下载,成为VIP会员后,下载免费。
- 5、成为VIP后,下载本文档将扣除1次下载权益。下载后,不支持退款、换文档。如有疑问请联系我们。
- 6、成为VIP后,您将拥有八大权益,权益包括:VIP文档下载权益、阅读免打扰、文档格式转换、高级专利检索、专属身份标志、高级客服、多端互通、版权登记。
- 7、VIP文档为合作方或网友上传,每下载1次, 网站将根据用户上传文档的质量评分、类型等,对文档贡献者给予高额补贴、流量扶持。如果你也想贡献VIP文档。上传文档
查看更多
不同给药方案噻托溴铵治疗哮喘合并慢阻肺疗效对比
不同给药方案的噻托溴铵治疗哮喘合并慢阻肺的疗效对比
【摘要】 目的 对比不同给药方案的噻托溴铵治疗哮喘合并慢性阻塞性肺疾病(慢阻肺)的临床疗效。方法 90例哮喘合并慢阻肺患者, 按照随机分配原则分为甲组和乙组, 各45例。甲组患者使用噻托溴铵粉吸入剂每日早晚各1次, 乙组患者使用噻托溴铵粉吸入剂仅1次/晚, 对比两组患者的临床疗效及不良反应发生情况。结果 甲组患者中显效31例、好转10例、无效4例, 乙组患者分别为30、12、3例, 对比差异无统计学意义(P0.05)。甲组患者不良反应发生率为6.67%, 乙组患者不良反应发生率为8.89%, 两组不良反应发生率对比, 差异无统计学意义(P0.05)。结论 不同给药方式的噻托溴铵在治疗哮喘合并慢阻肺时的临床疗效及安全性均较好, 临床工作中医生可向患者提供两种治疗方案供患者选择, 提高患者的依从性。
【关键词】 不同给药方案;噻托溴铵;哮喘;慢性阻塞性肺疾病
DOI:10.14163/j.cnki.11-5547/r.2018.08.046
Comparison of the efficacy of tiotropium bromide with different dosage regimens in the treatment of asthma complicated with chronic obstructive pulmonary disease MU Qing. Henan People’s Hospital, Zhengzhou 450000, China
【Abstract】 Objective To compare the clinical efficacy of tiotropium bromide with different dosage regimens in the treatment of asthma complicated with chronic obstructive pulmonary disease. Methods A total of 90 patients with asthma complicated with chronic obstructive pulmonary disease were randomly divided into group A and group B, with 45 cases in each group. Group A received tiotropium bromide powder for inhalation by 1 time in each morning and evening, and group B received tiotropium bromide powder for inhalation by 1 time/night. Comparison were made on clinical efficacy and occurrence of adverse reactions between the two groups. Results Group A had 31 excellent cases, 10 improved cases and 4 ineffective cases, which were 30, 12 and 3 cases in group B, and their difference was not statistically significant (P0.05). Group A had incidence of adverse reactions as 6.67%, which was 8.89% in group B, and both groups had no statistically significant difference in incidence of adverse reactions (P0.05). Conclusion Tiotropium bromide with different dosage regimens shows better clinical efficacy and safety in the treatment of asthma complicated with chronic obstructive pulmonary disease. Clinical doctors can provide patients with two kinds of treatment options for patient selection to improve pati
原创力文档


文档评论(0)